Arca
Skip to content
Tools
Tools

KCNH2: Voltage-gated inwardly rectifying potassium channel KCNH2

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel.

  • Drugs that act on it: 7
  • Approved: 5
  • In phases 1 to 3: 2
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on KCNH2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7

Approved5

  • Amiodarone
  • Sotalol
  • Dofetilide
  • Ibutilide
  • Vernakalant

Phase 30

    Phase 22

    • AZD1305
    • AZD7009

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: HERG blocker.
      AmiodaroneBoxed warningApprovedPfizerSmall moleculeBlocker49
      SotalolBoxed warningApprovedLEGACYSmall moleculeBlocker14
      DofetilideBoxed warningApprovedPfizerSmall moleculeBlocker3
      IbutilideBoxed warningApprovedPfizerSmall moleculeBlocker1
      VernakalantApprovedAstellas PharmaSmall moleculeBlocker1
      AZD1305Phase 2AstraZeneca PharmaceuticalsSmall moleculeBlocker0
      AZD7009Phase 2AstraZeneca PharmaceuticalsSmall moleculeBlocker0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
      Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)AmiodaroneNot applicableNot yet recruitingKorea University Anam HospitalNov 16, 2026
      Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a Posterior Pericardiotomy.AmiodaronePhase 3Not yet recruitingElsanOct 21, 2026
      Percutaneous Stellate Ganglion Block as First Line Treatment in Patients With Electrical Storm: the STAR 2 StudyAmiodaronePhase 3Not yet recruitingFondazione IRCCS Policlinico San Matteo di PaviaSep 25, 2026
      A Study on the Efficacy and Safety of TEER Combined With Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial FibrillationAmiodaroneNot applicableRecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineAug 3, 2026
      Efficacy of Early Rhythm Control in AF With TR PatientsAmiodarone, Sotalol—RecruitingSamsung Medical CenterMay 26, 2026
      Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)IbutilideNot applicableRecruitingChina National Center for Cardiovascular DiseasesMay 22, 2026
      Pharmacological Intervention to Prevent NOAF After TAVRAmiodaroneNot applicableNot yet recruitingShanghai East HospitalApr 9, 2026
      Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma ConcentrationAmiodaronePhase 4Enrolling by invitationTomsk National Research Medical Center of the Russian Academy of SciencesMar 23, 2026
      Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.AmiodaroneNot applicableNot yet recruitingSohag UniversityMar 5, 2026
      Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular ComplexesSotalolNot applicableRecruitingWestern Sydney Local Health DistrictMar 3, 2026
      Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial FibrillationSotalolNot applicableRecruitingSamsung Medical CenterMar 3, 2026
      Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationSotalolPhase 4RecruitingUniversitaire Ziekenhuizen KU LeuvenFeb 12, 2026
      Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm ControlDofetilide, Sotalol—Not yet recruitingKansas City Heart Rhythm Research FoundationJan 20, 2025
      Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic StrategiesSotalolNot applicableRecruitingIRCCS Ospedale San RaffaeleNov 1, 2024
      Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial FibrillationSotalolNot applicableRecruitingNantes University HospitalMar 20, 2024
      Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial FibrillationDofetilide, SotalolNot applicableActive, not recruitingBoston Scientific CorporationOct 23, 2023
      The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) PatientsDofetilidePhase 4RecruitingUniversity of RochesterSep 5, 2021
      Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery PatientsVernakalantPhase 3Not yet recruitingUniversity of CalgaryFeb 10, 2021

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Familial long QT syndrome0.85
      • Short QT syndrome0.78
      • Cardiac arrhythmia0.73
      • Prolonged QT interval0.71
      • Ventricular arrhythmia0.57
      • Abnormality of the cardiovascular system0.57
      • Lambert-Eaton myasthenic syndrome0.56

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL240, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q12809, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.